News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nimbus Discovery To Present Data Showing That Selective ACC Inhibitors Dramatically Impact Tumor Growth In Pre-Clinical Models At American Association for Cancer Research Annual Meeting 2014



4/2/2014 9:37:38 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible drug targets, today announced that data on its Acetyl CoA Carboxylase (ACC) program will be presented at the 105th Annual Meeting of the American Association for Cancer Research. Nimbus will present data in two abstracts showing activity with ND-646 and ND-654 in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) respectively. The conference will take place on April 5-9th at the Diego Convention Center, San Diego, California.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES